Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302 Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number					
1. REPORT DATE 2. REPORT TYPE			3. DATES COVERED		
12 DEC 2012	12 DEC 2012 N/A			-	
4. TITLE AND SUBTITLE				5a. CONTRACT NUMBER	
Cyanide poisoning and antidotes				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Bebarta V. S.,				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF: 17. LIMI				18. NUMBER	19a. NAME OF
a REPORT unclassified	b ABSTRACT unclassified	c THIS PAGE unclassified	- ABSTRACT UU	OF PAGES 2	RESPONSIBLE PERSON

Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std Z39-18



doi: 10.1111/1742-6723.12004

LETTER TO THE EDITOR



Cyanide poisoning and antidotes

Dear Editor,

We read with interest the review article by Reade et al. titled, 'Review article: Management of cyanide poisoning'.¹ The article was a succinct review of current treatment guidelines for cyanide treatment. We concur with several of the authors' recommendations that had not been clearly stated in other reviews or reports. In particular, we agree that in cyanide-induced cardiac arrest, patients should receive hydroxocobalamin preferentially and repeat dosing as needed. We also agree that based on adverse effects alone, hydroxocobalamin might be a better choice for cyanide toxicity; in addition, we note a comparative study has been reported comparing sodium nitrite with hydroxocobalamin.² Finally, we also concur that the guidelines by the UK, which do not recommend antidotal treatment, are not based on current published evidence and that antidotes are effective for cyanide toxicity.

However, we disagree on three areas. First, the authors report that studies comparing supportive care with use of antidote have not been conducted; however, we reported a comparative trial between supportive care and antidotal therapy and found that supportive care in a cardiac arrest model is 100% lethal.³ Second, the authors report that most studies used thiosulphate in combination with antidotes and that there is evidence that sodium thiosulphate is effective alone. However, we reported a clinically relevant, critically ill model of cyanide-induced hypotension demonstrating that sodium thiosulphate is not effective alone and had 100% mortality.⁴ Finally, we disagree with the authors that sodium thiosulphate should be used following failure to respond to hydroxocobalamin. We demonstrated that sodium thiosulphate does not improve efficacy when combined with hydroxocobalamin.⁴ In

addition, based on previous animal and human studies, if the patient does not respond to the vasopressor or antidotal effects of hydroxocobalamin, the patient is unlikely to receive benefit from sodium thiosulphate, a drug that might take up to 30 min to take effect and is poorly transported into the mitochondrial membrane, hydroxocobalamin's site of action.⁴⁵

Competing interests

None declared.

References

- Reade MC, Davies SR, Morley PT, Dennett J, Jacobs IC. Review article: Management of cyanide poisoning. *Emerg. Med. Aus*tralas. 2012; 24: 225–38.
- Bebarta VS, Tanen DA, Lairet J, Dixon PS, Valtier S, Bush A. Hydroxocobalamin and sodium thiosulfate versus sodium nitrite and sodium thiosulfate in the treatment of acute cyanide toxicity in a swine (Sus scrofa) model. *Ann. Emerg. Med.* 2010; 55: 345–51.
- Bebarta VS, Pitotti RL, Dixon PS *et al.* Hydroxocobalamin and epinephrine both improve survival in a swine model of cyanideinduced cardiac arrest. *Ann. Emerg. Med.* 2012; 60: 415–22.
- Bebarta VS, Pitotti RL, Dixon P, Lairet JR, Bush A, Tanen DA. Hydroxocobalamin versus sodium thiosulfate for the treatment of acute cyanide toxicity in a swine (Sus scrofa) model. *Ann. Emerg. Med.* 2012; 59: 532–9.
- Fortin JL, Giocanti JP, Ruttimann M, Kowalski JJ. Prehospital administration of hydroxocobalamin for smoke inhalationassociated cyanide poisoning: 8 years of experience in the Paris Fire Brigade. *Clin. Toxicol.* 2006; 44 (Suppl 1): 37–44.

Vikhyat S Bebarta Medical Toxicology, Department of Emergency Medicine, San Antonio Military Medical Center, San Antonio, Texas, USA Copyright of Emergency Medicine Australasia is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.